Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. 2009

David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
Chemical Sciences, Wyeth Research, CN 8000 Princeton, NJ 08543, United States. rotelld@wyeth.com

A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.

UI MeSH Term Description Entries
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin
D017448 Receptors, Dopamine D2 A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES. Dopamine D2 Receptors,Dopamine-D2 Receptor,D2 Receptors, Dopamine,Dopamine D2 Receptor,Receptor, Dopamine-D2
D044282 Receptor, Serotonin, 5-HT1A A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION. Serotonin 1A Receptor,5-HT(1A) Receptor,5-HT1A Receptor,5-Hydroxytryptamine 1A Receptor,5-Hydroxytryptamine 1A Receptors,Receptor, 5-Hydroxytryptamine 1A,Serotonin Receptor, 5-HT1A,Serotonin, 5-HT1a Receptor,1A Receptor, 5-Hydroxytryptamine,1A Receptors, 5-Hydroxytryptamine,5 HT1A Receptor,5 Hydroxytryptamine 1A Receptor,5 Hydroxytryptamine 1A Receptors,5-HT1A Serotonin Receptor,5-HT1a Receptor Serotonin,Receptor Serotonin, 5-HT1a,Receptor, 5 Hydroxytryptamine 1A,Receptor, 5-HT1A,Receptor, 5-HT1A Serotonin,Receptor, Serotonin 1A,Receptors, 5-Hydroxytryptamine 1A,Serotonin Receptor, 5 HT1A,Serotonin, 5 HT1a Receptor
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D058829 Serotonin 5-HT1 Receptor Antagonists Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes. 5-HT1 Antagonist,5-HT1 Antagonists,5-HT1A Antagonist,5-HT1B Antagonist,5-HT1B-D Antagonist,5-HT1D Antagonist,Serotonin 5-HT1A Receptor Antagonists,Serotonin 5-HT1B Receptor Antagonists,Serotonin 5-HT1B-D Antagonists,Serotonin 5-HT1D Receptor Antagonists,5 HT1 Antagonist,5 HT1 Antagonists,5 HT1A Antagonist,5 HT1B Antagonist,5 HT1B D Antagonist,5 HT1D Antagonist,5-HT1B-D Antagonists, Serotonin,Antagonist, 5-HT1,Antagonist, 5-HT1A,Antagonist, 5-HT1B,Antagonist, 5-HT1B-D,Antagonist, 5-HT1D,Antagonists, 5-HT1,Antagonists, Serotonin 5-HT1B-D,Serotonin 5 HT1 Receptor Antagonists,Serotonin 5 HT1A Receptor Antagonists,Serotonin 5 HT1B D Antagonists,Serotonin 5 HT1B Receptor Antagonists,Serotonin 5 HT1D Receptor Antagonists
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
May 2010, Bioorganic & medicinal chemistry letters,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
January 1989, Psychopharmacology bulletin,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
May 2020, CNS drugs,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
October 2010, Bioorganic & medicinal chemistry letters,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
May 2005, Hospital medicine (London, England : 1998),
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
January 2008, Current topics in medicinal chemistry,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
April 1999, The Annals of pharmacotherapy,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
May 2019, Journal of medicinal chemistry,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
February 1999, Neuroreport,
David P Rotella, and Geraldine R McFarlane, and Alexander Greenfield, and Cristina Grosanu, and Albert J Robichaud, and Rajiah Aldrin Denny, and Rolf W Feenstra, and Sara Núñez-García, and Jan-Hendrik Reinders, and Martina van der Neut, and Andrew McCreary, and Chris G Kruse, and Kelly Sullivan, and Farhana Pruthi, and Margaret Lai, and Jean Zhang, and Dianne M Kowal, and Tikva Carrick, and Steven M Grauer, and Rachel L Navarra, and Radka Graf, and Julie Brennan, and Karen L Marquis, and Mark H Pausch
June 2000, The Annals of pharmacotherapy,
Copied contents to your clipboard!